Pembrolizumab Plus Lenvatinib for Previously Untreated Advanced Non–Clear Cell Renal Cell Carcinoma: 3-Year Follow-Up of the Phase 2 KEYNOTE-B61 Study

home / between-the-lines / pembrolizumab-plus-lenvatinib-for-previously-untreated-advanced-non-clear-cell-renal-cell

Panelists discuss how the 3-year follow-up data from the KEYNOTE-B61 study demonstrate that pembrolizumab plus lenvatinib represents a new standard of care for advanced non–clear cell renal cell carcinoma (RCC), achieving impressive response rates of approximately 51%, median progression-free survival of 17.9 months, and median overall survival of 41.5 months across various histological subtypes, including papillary, chromophobe, translocation, and unclassified RCC.

2 KOLs are featured in this series.

EP. 1: Introducing KEYNOTE-B61 in Non–Clear Cell RCC

Moshe Ornstein, MD, MA;Yasser Ged, MBBS
September 12th 2025

Panelists discuss how they will review the KEYNOTE-B61 phase 2 study examining pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma (RCC), including an overview of non–clear cell RCC and integration of the 3-year follow-up data into clinical practice.

2 KOLs are featured in this series.

EP. 2: Challenges in Treating Non–Clear Cell RCC

Moshe Ornstein, MD, MA;Yasser Ged, MBBS
September 12th 2025

Panelists discuss how non–clear cell renal cell carcinoma (RCC) represents a challenging, heterogeneous collection of rare tumors comprising 25% to 30% of all RCC cases, requiring careful histological review and individualized risk stratification based on tumor biology, disease tempo, and burden rather than traditional treatment algorithms used for clear cell RCC.